Today the National Institute for Health and Care Excellence (NICE) has rejected the use of afilbercept (Zaltrap) on the NHS in England and Wales.
Afilbercept is used for patients with bowel cancer in advanced stages when it has spread to other organs.
Mark Flannagan, Chief Executive of the charity Beating Bowel Cancer, said: “We are disappointed by NICE’s decision, as patients with advanced bowel cancer currently have very few options open to them for treatment that could prolong their lives.
read more